Skip to content
Clinical Trials – home

Universita Cattolica Del Sacro Cuore

Verifiedinfo

Italy Largo Agostino Gemelli 8, 00168 Rome, Italy

  • 9 trials recruiting
  • Chronic lymphocytic leukaemia · Breast cancer · Diffuse large B-cell lymphoma
  • Adults and children

About Specializations

Universita Cattolica Del Sacro Cuore in Rome, Italy specialises in clinical trials of conditions such as Chronic lymphocytic leukaemia, Breast cancer, Diffuse large B-cell lymphoma, Bladder transitional cell carcinoma, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology and Immune-Mediated Disease

The research program at Universita Cattolica Del Sacro Cuore includes studies in digestive system diseases and immune system diseases, with a strong focus on Crohn’s disease, lupus nephritis, and non-alcoholic steatohepatitis. These trials are designed to test new treatment options and better understand how to control inflammation and organ damage over time.

  • Inflammatory bowel disease, especially Crohn’s disease
  • Autoimmune kidney disease and systemic immune disorders
  • Chronic liver disease linked to metabolic dysfunction

Overall, this area reflects a broad effort to improve symptom control, slow disease progression, and support more effective long-term care.

Oncology and Hematologic Malignancies

A major part of the clinical trial activity centers on neoplasms and hemic and lymphatic diseases, covering cancers such as breast cancer, ovarian cancer, lung cancer, prostate cancer, bladder cancer, and several forms of lymphoma and leukemia. These studies mainly aim to evaluate new therapies, compare treatment strategies, and improve outcomes for patients with advanced or hard-to-treat disease.

  • Solid tumors including breast, lung, prostate, ovarian, gastric, and bladder cancers
  • Blood cancers such as diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, Hodgkin’s lymphoma, and chronic lymphocytic leukemia
  • Research focused on treatment effectiveness, survival, and disease control

This is one of the most active therapeutic areas at the site, showing a strong commitment to innovative cancer care and precision oncology.

Neurology and Rare Diseases

The site also supports trials in nervous system diseases and congenital, hereditary, and neonatal disorders, including epilepsy, spinal muscular atrophy, and rare seizure syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. These studies are focused on improving safety, long-term disease management, and quality of life for people living with complex neurological conditions.

  • Drug-resistant focal seizures and rare epilepsy syndromes
  • Spinal muscular atrophy and long-term follow-up care
  • Studies aimed at better symptom control and ongoing safety monitoring

Research in this field highlights the site’s interest in conditions where treatment options remain limited and careful follow-up is especially important.

Cardiovascular, Musculoskeletal, and Autoimmune Research

Clinical trials in cardiovascular diseases, musculoskeletal diseases, and immune-mediated disorders explore conditions such as atherosclerotic cardiovascular disease, systemic sclerosis, idiopathic inflammatory myopathy, and plaque psoriasis. The purpose of this research is to assess whether new therapies can better prevent complications, improve disease response, and reduce the burden of chronic illness.

  • Cardiovascular risk reduction and prevention of major events
  • Autoimmune and inflammatory diseases affecting the skin, muscles, and connective tissue
  • Trials evaluating clinical improvement and treatment benefit over time

At this Rome-based research site, these studies contribute to a wider precision-medicine approach that connects internal medicine, immunology, and chronic disease management.

Infectious Disease and Specialized Supportive Care

Another important research direction involves bacterial infections and mycoses, especially invasive fungal infections caused by Aspergillus species. These trials are designed to compare treatment options and improve care for serious infections in vulnerable patients.

  • Severe fungal disease and treatment response
  • Supportive research for complex, high-risk clinical settings
  • Evaluation of new approaches to infection management

This field adds an important infectious-disease dimension to the broader clinical portfolio at Universita Cattolica Del Sacro Cuore.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Largo Agostino Gemelli 800168 RomeItaly
Recruiting now
9 trials
Conditions studied
51
Partner status
Verified

More sites in RomeItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

36 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Nurix Therapeutics Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Fondazione Italiana Linfomi Ets
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.